Efficacy of immune checkpoint inhibitors in advanced non‐small cell lung cancer patients with KRAS mutations: A network meta‐analysis

Documenti analoghi

• Efficacy and safety of PD‐1/PD‐L1 inhibitors in elderly patients with advanced non‐small cell lung cancer
  di: Li Li, et al.
  Pubblicazione: (2024)
• The impact of EGFR T790M mutation status following the development of Osimertinib resistance on the efficacy of Osimertinib in non‐small cell lung cancer: A meta‐analysis
  di: Liuxian Guo, et al.
  Pubblicazione: (2024)
• Efficacy of neoadjuvant chemotherapy combined with surgery in patients with nonsmall cell lung cancer: A meta‐analysis
  di: Hai‐jun Dong, et al.
  Pubblicazione: (2024)
• The inhibitory effect of apatinib on different small cell lung cancer cells and in lung cancer‐bearing mice and patients
  di: Mingtao Liu, et al.
  Pubblicazione: (2024)
• Prognostic utility of blood inflammation biomarkers before and after treatment on the survival of patients with locally advanced non‐small cell lung cancer undergoing stereotactic body radiotherapy
  di: Fang Fang, et al.
  Pubblicazione: (2024)